Injection of an improperly stored proprotein convertase subtilisin/kexin type 9 monoclonal antibody in a patient with secondary dyslipidemia from nephrotic syndrome: a case report

Abstract Background Elevated plasma cholesterol and/or plasma triglyceride levels in nephrotic syndrome patients are the result of impaired lipoprotein clearance and a compensatory increase in hepatic lipoprotein synthesis. Plasma proprotein convertase subtilisin/kexin type 9 levels directly correla...

Full description

Bibliographic Details
Main Authors: Tanawan Kongmalai, Nalinee Chuanchaiyakul, Yuttana Srinoulprasert, Nuntakorn Thongtang
Format: Article
Language:English
Published: BMC 2023-03-01
Series:Journal of Medical Case Reports
Subjects:
Online Access:https://doi.org/10.1186/s13256-023-03804-5
_version_ 1797864633038536704
author Tanawan Kongmalai
Nalinee Chuanchaiyakul
Yuttana Srinoulprasert
Nuntakorn Thongtang
author_facet Tanawan Kongmalai
Nalinee Chuanchaiyakul
Yuttana Srinoulprasert
Nuntakorn Thongtang
author_sort Tanawan Kongmalai
collection DOAJ
description Abstract Background Elevated plasma cholesterol and/or plasma triglyceride levels in nephrotic syndrome patients are the result of impaired lipoprotein clearance and a compensatory increase in hepatic lipoprotein synthesis. Plasma proprotein convertase subtilisin/kexin type 9 levels directly correlate to the amount of proteinuria in nephrotic syndrome patients. Proprotein convertase subtilisin/kexin type 9 monoclonal antibody has been used to treat dyslipidemia in some refractory nephrotic syndrome cases. As a therapeutic protein, proprotein convertase subtilisin/kexin type 9 monoclonal antibody simply deteriorates if stored in inappropriate temperatures or conditions. Case presentation In this article, we present the case of a 16-year-old Thai female with severe combined dyslipidemia secondary to refractory nephrotic syndrome. She received proprotein convertase subtilisin/kexin type 9 monoclonal antibody (alirocumab) treatment. However, the drugs were mistakenly frozen in a freezer for up to 17 hours before being stored at 4 °C. After using two frozen devices, serum total cholesterol, free proprotein convertase subtilisin/kexin type 9, and lipoprotein(a) significantly decreased. Nonetheless, the patient developed a skin rash 2 weeks after the second injection and the lesion spontaneously resolved without any treatment approximately 1 month later. Conclusions The effectiveness of proprotein convertase subtilisin/kexin type 9 monoclonal antibody seems to be stable after being stored under freeze–thaw conditions. However, improperly stored drugs should be discarded to avoid any potential undesirable side effects.
first_indexed 2024-04-09T22:55:02Z
format Article
id doaj.art-73718f4582cb4fee93e531e5abab6904
institution Directory Open Access Journal
issn 1752-1947
language English
last_indexed 2024-04-09T22:55:02Z
publishDate 2023-03-01
publisher BMC
record_format Article
series Journal of Medical Case Reports
spelling doaj.art-73718f4582cb4fee93e531e5abab69042023-03-22T11:19:32ZengBMCJournal of Medical Case Reports1752-19472023-03-011711610.1186/s13256-023-03804-5Injection of an improperly stored proprotein convertase subtilisin/kexin type 9 monoclonal antibody in a patient with secondary dyslipidemia from nephrotic syndrome: a case reportTanawan Kongmalai0Nalinee Chuanchaiyakul1Yuttana Srinoulprasert2Nuntakorn Thongtang3Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol UniversityDivision of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol UniversityDepartment of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol UniversityDivision of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol UniversityAbstract Background Elevated plasma cholesterol and/or plasma triglyceride levels in nephrotic syndrome patients are the result of impaired lipoprotein clearance and a compensatory increase in hepatic lipoprotein synthesis. Plasma proprotein convertase subtilisin/kexin type 9 levels directly correlate to the amount of proteinuria in nephrotic syndrome patients. Proprotein convertase subtilisin/kexin type 9 monoclonal antibody has been used to treat dyslipidemia in some refractory nephrotic syndrome cases. As a therapeutic protein, proprotein convertase subtilisin/kexin type 9 monoclonal antibody simply deteriorates if stored in inappropriate temperatures or conditions. Case presentation In this article, we present the case of a 16-year-old Thai female with severe combined dyslipidemia secondary to refractory nephrotic syndrome. She received proprotein convertase subtilisin/kexin type 9 monoclonal antibody (alirocumab) treatment. However, the drugs were mistakenly frozen in a freezer for up to 17 hours before being stored at 4 °C. After using two frozen devices, serum total cholesterol, free proprotein convertase subtilisin/kexin type 9, and lipoprotein(a) significantly decreased. Nonetheless, the patient developed a skin rash 2 weeks after the second injection and the lesion spontaneously resolved without any treatment approximately 1 month later. Conclusions The effectiveness of proprotein convertase subtilisin/kexin type 9 monoclonal antibody seems to be stable after being stored under freeze–thaw conditions. However, improperly stored drugs should be discarded to avoid any potential undesirable side effects.https://doi.org/10.1186/s13256-023-03804-5Nephrotic syndromeDyslipidemiaPCSK9 monoclonal antibodyPCSK9 storageTemperatureCase report
spellingShingle Tanawan Kongmalai
Nalinee Chuanchaiyakul
Yuttana Srinoulprasert
Nuntakorn Thongtang
Injection of an improperly stored proprotein convertase subtilisin/kexin type 9 monoclonal antibody in a patient with secondary dyslipidemia from nephrotic syndrome: a case report
Journal of Medical Case Reports
Nephrotic syndrome
Dyslipidemia
PCSK9 monoclonal antibody
PCSK9 storage
Temperature
Case report
title Injection of an improperly stored proprotein convertase subtilisin/kexin type 9 monoclonal antibody in a patient with secondary dyslipidemia from nephrotic syndrome: a case report
title_full Injection of an improperly stored proprotein convertase subtilisin/kexin type 9 monoclonal antibody in a patient with secondary dyslipidemia from nephrotic syndrome: a case report
title_fullStr Injection of an improperly stored proprotein convertase subtilisin/kexin type 9 monoclonal antibody in a patient with secondary dyslipidemia from nephrotic syndrome: a case report
title_full_unstemmed Injection of an improperly stored proprotein convertase subtilisin/kexin type 9 monoclonal antibody in a patient with secondary dyslipidemia from nephrotic syndrome: a case report
title_short Injection of an improperly stored proprotein convertase subtilisin/kexin type 9 monoclonal antibody in a patient with secondary dyslipidemia from nephrotic syndrome: a case report
title_sort injection of an improperly stored proprotein convertase subtilisin kexin type 9 monoclonal antibody in a patient with secondary dyslipidemia from nephrotic syndrome a case report
topic Nephrotic syndrome
Dyslipidemia
PCSK9 monoclonal antibody
PCSK9 storage
Temperature
Case report
url https://doi.org/10.1186/s13256-023-03804-5
work_keys_str_mv AT tanawankongmalai injectionofanimproperlystoredproproteinconvertasesubtilisinkexintype9monoclonalantibodyinapatientwithsecondarydyslipidemiafromnephroticsyndromeacasereport
AT nalineechuanchaiyakul injectionofanimproperlystoredproproteinconvertasesubtilisinkexintype9monoclonalantibodyinapatientwithsecondarydyslipidemiafromnephroticsyndromeacasereport
AT yuttanasrinoulprasert injectionofanimproperlystoredproproteinconvertasesubtilisinkexintype9monoclonalantibodyinapatientwithsecondarydyslipidemiafromnephroticsyndromeacasereport
AT nuntakornthongtang injectionofanimproperlystoredproproteinconvertasesubtilisinkexintype9monoclonalantibodyinapatientwithsecondarydyslipidemiafromnephroticsyndromeacasereport